Announcement • Apr 27
Genesis Scale Holdings Limited, Annual General Meeting, Jun 30, 2026 Genesis Scale Holdings Limited, Annual General Meeting, Jun 30, 2026, at 11:00 China Standard Time. Location: 10/f., united centre, 95 queensway, admiralty, Hong Kong Announcement • Mar 13
Genesis Scale Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026 Genesis Scale Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026 Announcement • Feb 17
Genesis Scale Holdings Limited Provides Unaudited Consolidated Earning Guidance for Year Ended 31 December 2025 Genesis Scale Holdings Limited provided unaudited consolidated earning guidance for year ended 31 December 2025. For the year, the Group expects that it may record an increase in net loss for Full Year 2025, with a net loss ranging from approximately HKD 130 million to HKD 150 million, compared to a net loss of approximately HKD 47.4 million for the year ended 31 December 2024 (“Full Year 2024”). The primary reason for this increase in net loss is attributable to the provision of a claim of approximately HKD 118 million in relation to the dispute of a subsidiary involved in the legal proceedings, the status of which was previously disclosed in the Company's announcement dated 16 December 2025, titled "Update on a Legal Proceeding Involving a Subsidiary". Announcement • Aug 15
KuangChi Science Limited to Report First Half, 2025 Results on Aug 29, 2025 KuangChi Science Limited announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • May 29
KuangChi Science Limited, Annual General Meeting, Jun 27, 2025 KuangChi Science Limited, Annual General Meeting, Jun 27, 2025, at 11:00 China Standard Time. Location: 10/f, united centre, 95 queensway, admiralty, Hong Kong Announcement • Mar 14
KuangChi Science Limited to Report Q4, 2024 Results on Mar 28, 2025 KuangChi Science Limited announced that they will report Q4, 2024 results at 4:00 PM, China Standard Time on Mar 28, 2025 New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$116m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€62.2m market cap, or US$68.9m). Reported Earnings • Sep 25
First half 2024 earnings released: HK$0.008 loss per share (vs HK$0.015 loss in 1H 2023) First half 2024 results: HK$0.008 loss per share (improved from HK$0.015 loss in 1H 2023). Revenue: HK$32.0m (down 4.3% from 1H 2023). Net loss: HK$5.23m (loss narrowed 43% from 1H 2023). Announcement • Aug 16
KuangChi Science Limited to Report First Half, 2024 Results on Aug 30, 2024 KuangChi Science Limited announced that they will report first half, 2024 results on Aug 30, 2024 New Risk • Aug 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (€37.5m market cap, or US$41.1m). Reported Earnings • Mar 29
Full year 2023 earnings released: HK$0.012 loss per share (vs HK$0.11 loss in FY 2022) Full year 2023 results: HK$0.012 loss per share (improved from HK$0.11 loss in FY 2022). Revenue: HK$83.1m (up 58% from FY 2022). Net loss: HK$7.30m (loss narrowed 89% from FY 2022). Announcement • Mar 16
KuangChi Science Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 KuangChi Science Limited announced that they will report fiscal year 2023 results on Mar 27, 2024 Board Change • Mar 11
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Zhili Wu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 04
First half 2023 earnings released: HK$0.001 loss per share (vs HK$0.006 loss in 1H 2022) First half 2023 results: HK$0.001 loss per share (improved from HK$0.006 loss in 1H 2022). Net loss: HK$9.10m (loss narrowed 76% from 1H 2022). Announcement • Aug 16
KuangChi Science Limited to Report First Half, 2023 Results on Aug 30, 2023 KuangChi Science Limited announced that they will report first half, 2023 results on Aug 30, 2023 Announcement • May 30
KuangChi Science Limited, Annual General Meeting, Jun 30, 2023 KuangChi Science Limited, Annual General Meeting, Jun 30, 2023, at 11:00 China Standard Time. Location: 2nd Floor, Software Building, No. 9 Gaoxin Middle 1st Road, Nanshan District, Shenzhen Guangdong Province China Agenda: To consider receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the "Director(s)") and of the auditor of the Company for the year ended 31 December 2022; to consider re-elect retiring Directors; to consider authorise the board of Directors to fix the remuneration of the Directors; to consider re-appoint RSM Hong Kong as the auditor of the Company. Announcement • May 09
Kuangchi Science Limited Announces Board Changes KuangChi Science Limited announced that the Board announced that with effect from 8 May 2023 Dr. Deng Ke has resigned as an Independent Non-executive Director, a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company; and Dr. Wu Zhili has been appointed as an Independent Non-executive Director, a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company. Dr. Wu Zhili ("Dr. Wu"), aged 42, graduated from Hong Kong Baptist University in 2002, majoring in computer science and obtained a bachelor's degree. He has been studying in Hong Kong Baptist University thereafter and obtained a master's degree and a doctoral degree in 2004 and 2008, respectively. Dr. Wu engaged in post-doctoral research at Hong Kong Baptist University from 2008 to 2009, while he engaged in post-doctoral research at the University of Leeds in the United Kingdom from 2009 to 2010. Dr. Wu has served as a senior researcher in Ericsson Research Institute and has worked as the chief AI officer and data officer in various companies. Afterwards, since 2017, Mr. Wu founded Shenzhen Yiyuan Intelligent Technology Co. Ltd. . Yiyuan Intelligent focuses on the application of AI technology on the product development and expansion in the field of skin image segmentation and is actively expanding the feasibility of implementing AI-assisted dermatosis diagnosis and treatment in hospitals. In addition to serving as visiting professor and external hire lecturer, Dr. Wu has published numerous articles in relation to the artificial intelligence sector, with an aim to contribute to the technology and research of artificial intelligence. By an appointment letter entered into with the Company on 8 May 2023, Dr. Wu shall serve as an Independent Non-executive Director for a term of three years but he will be subject to re-election at the next general meeting of the Company in accordance with the bye-laws of the Company. The director's fee payable to him is fixed at the rate of HKD 250,000 per annum, which was reviewed by the Remuneration Committee of the Company and determined by the Board with reference to his experience, duties and responsibilities in the Company as well as the current market rate. The Board further announces that following the resignation of Dr. Deng as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company and Dr. Wu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company with effect from 8 May 2023. Reported Earnings • Apr 02
Full year 2022 earnings released: HK$0.011 loss per share (vs HK$0.007 loss in FY 2021) Full year 2022 results: HK$0.011 loss per share (further deteriorated from HK$0.007 loss in FY 2021). Net loss: HK$67.9m (loss widened 67% from FY 2021). Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-executive Director Ke Deng was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
First half 2022 earnings released: HK$0.006 loss per share (vs HK$0.002 loss in 1H 2021) First half 2022 results: HK$0.006 loss per share (down from HK$0.002 loss in 1H 2021). Revenue: HK$30.9m (up 109% from 1H 2021). Net loss: HK$38.5m (loss widened 169% from 1H 2021). Board Change • Apr 28
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-executive Director Ke Deng was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
Full year 2021 earnings released: HK$0.007 loss per share (vs HK$0.013 loss in FY 2020) Full year 2021 results: HK$0.007 loss per share (up from HK$0.013 loss in FY 2020). Revenue: HK$114.0m (up 15% from FY 2020). Net loss: HK$40.6m (loss narrowed 47% from FY 2020). Board Change • Dec 01
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-executive Director Ke Deng was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
